Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers Number Effective Date Revision Date(s) Replaces 2.04.76 February 9, 2016 02/09/16; 12/08/15; 12/7/14; 12/09/13; 12/19/12;12/13/11 N/A Policy [TOP] The assessment of HER2 status by quantitative total HER2 protein expression and HER2 homodimer measurement is considered investigational. Related Policies [TOP] 5.01.514 Trastuzumab and Other HER2 Inhibitors Policy Guidelines [TOP] Coding CPT 84999 Unlisted Chemistry procedure Description [TOP] Novel assays that quantitatively measure total human epidermal growth factor receptor 2 (HER2) protein expression and homodimers have been developed to improve the accuracy and consistency of HER2 testing. The evidence for assessment of HER2 status using quantitative total HER2 protein expression and HER2 homodimer measurement in patients who have breast cancer and are undergoing assessment of HER2 status includes validation studies and retrospective analysis of association between levels and survival outcomes. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Retrospective analysis using HERmark® have shown that the assay may predict a worse response to trastuzumab in certain populations. However, findings have been inconsistent, and no clear association with clinical outcomes has been shown. Additionally, cut points for defining patient groups varied across studies. Clinical utility of the HERmark® assay has not been demonstrated, and clinical trials are needed to determine the impact on clinical outcomes of patients stratified by the HERmark® assay. The evidence is insufficient to determine the effects of the technology on health outcomes. Background The HER family of receptor tyrosine kinases (EGFR/HER1, ErbB2/HER2, ErbB3/HER3, ErbB4/HER4) plays a major role in the pathogenesis of many solid tumors. In approximately 25% to 30% of breast cancers, overexpression of HER2 has been linked to shorter disease-free (DFS) and overall survival (OS), lack of responsiveness to tamoxifen antiestrogen therapy, and altered responsiveness to a variety of cytotoxic chemotherapy regimens. Trastuzumab, a monoclonal antibody directed at the extracellular domain of HER2 has offered significant DFS and OS advantages in the metastatic and adjuvant settings in HER2-overexpressing patients, although not all patients respond. Fewer than 50% of patients with metastatic HER2-positive breast cancer show initial benefit from trastuzumab treatment, and many of those eventually develop resistance. (1) Current methodologies for the selection of HER2-positive patients include immunohistochemistry (IHC) to detect HER2 protein overexpression, and fluorescence in situ hybridization (FISH) to detect HER2 gene amplification. However, controversy still exists regarding the accuracy, reliability, and interobserver variability of these assay methods. IHC provides a semiquantitative measure of protein levels (scored as 0, 1+, 2+, 3+) and the interpretation may be subjective. FISH is a quantitative measurement of gene amplification, in which the HER2 gene copy number is counted. However, FISH, which is considered to be more quantitative analytically, is not always representative of protein expression, and multiple studies have failed to demonstrate a relationship between HER2 gene copy number and response to trastuzumab. Whereas patients who overexpress HER2 protein (IHC) or show evidence of HER2 gene amplification (FISH) have been shown to experience better outcomes on trastuzumab than those scored negative by those assays, differences in the degree of expression or amplification by these methods have generally not been shown to discriminate between groups with different outcomes. IHC and FISH testing may be affected by interlaboratory variability, and neither test provides quantitative data that reflect the activation state of signaling pathways in tumors, which may limit their utility in patient selection. (2) Most laboratories in North America and Europe use IHC to determine HER2 protein status, with equivocal category results (2+) confirmed by FISH (or more recently by chromogenic in situ hybridization [CISH]). Normally, HER2 activates signaling pathways by dimerizing with ligand-bound EGFR-family members such as HER1 and HER3. A HER2 ligand has not been identified, but overexpressed HER2 is constitutively active. When HER2 is pathologically overexpressed, the receptor may homodimerize and activate signaling cascades in the absence of the normal regulatory control imposed by the requirement for ligand binding of its heterodimerization partners. A novel assay (HERmark® Breast Cancer Assay; Monogram Biosciences, South San Francisco, CA) was developed to quantify total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffin-embedded (FFPE) tissue samples. Regulatory Status Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratorydeveloped tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA). HERmark® is available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test. Scope [TOP] Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage. Benefit Application [TOP] N/A Rationale [TOP] Populations Individuals: With breast cancer who are undergoing assessment of HER2 status Interventions Interventions of interest are: Assessment of HER2 status using quantitative total HER2 protein expression and HER2 homodimer measurement Comparators Comparators of interest are: Assessment of HER2 status using immunohistochemistry or fluorescence in situ hybridization Outcomes Relevant outcomes include: Overall survival Disease-specific survival Test accuracy Test validity This policy was created in 2011 with the most recent MEDLINE literature search performed through November 12, 2015. Validation of biomarker assessment to improve treatment outcomes is a multistep process. In general, important steps in the validation process address the following: Analytic validity: measures technical performance, i.e., whether the test accurately and reproducibly detects the biomarker of interest. Clinical validity: measures the strength of the associations between the selected biomarkers and clinical status. Clinical utility: determines whether the use of specific biomarker assessments to guide treatment decisions improves patient outcomes such as survival or adverse event rate compared with standard treatment without genotyping. Analytic Validity The HERmark® assay uses a proprietary, proximity-based platform (proximity ligation assay) to measure total HER2 protein expression (H2T) and HER2 homodimers (H2D). Antibody binding to HER2 and other HER proteins releases fluorescent reporter tags (VeraTag™, Monogram Biosciences). Proximity of a bound HER2 antibody to a different bound HER antibody indicates a HER2 protein (H2T); proximity of 2 bound HER2 antibodies indicates a HER2 homodimer (H2D). Quantification of fluorescence permits quantification of H2T and H2D. The HERmark® assay is currently commercially available only for quantification of H2T and H2D in breast cancer. The company plans to validate use of the HERmark® test to measure HER heterodimers. The company website indicates that assays currently are available for HER2:HER1 and HER2:HER3 heterodimers; these apparently are for use in drug development. (3) HER2 protein quantification was normalized to tumor area and compared with receptor numbers in 12 human tumor cell lines (determined by fluorescence-activated cell sorting and standard immunohistochemistry [IHC]) and to IHC categories in 170 human breast tumors. (2) In contrast to conventional IHC test categories, HER2 protein levels determined by the VeraTag™ assay represent a continuous measurement over a dynamic range greater than 2 log10, and HER2 homodimer levels were consistent with crosslinking and immunoprecipitation results. Huang et al. (2010) compared results of the HERmark® assay with those of IHC and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic in 237 archived formalin-fixed, paraffin-embedded (FFPE) breast cancers. (4) IHC had already been performed at the time of initial diagnosis in all of the cases but was repeated for the purpose of this validation, and interpreted by one reviewer and scored as negative, equivocal, or positive according to the American Society of Clinical Oncologists/College of American Pathologists guidelines. (5) Reflex FISH for HER2 gene amplification also had been performed at the time of initial diagnosis on all 94 of the IHC 2+ cases. Repeat FISH was performed at the same laboratory and an overall evaluation performed by one pathologist. Of the 84 cases in the immunohistochemically negative subgroup, 80 (95%), 2 (2%), and 2 (2%) were classified as negative, equivocal, and positive by HERmark®, respectively. Of the 101 cases in the immunohistochemically equivocal subgroup, 33 (32.7%), 31 (30.7%), and 37 (36.6%) were classified as negative, equivocal, and positive by HERmark®, respectively. Of the 52 cases in the immunohistochemically positive subgroup, 1 (2%), 3 (6%), and 48 (92%) were classified as negative, equivocal, and positive by HERmark®, respectively. Overall concordance was 67%, with a weighted κ of 63% (95% confidence interval [CI], 55% to 70%). When equivocal cases were excluded from the HERmark® and IHC results, positive and negative concordance between HERmark® and central immunohistochemical testing was 98%, and overall concordance was 98%, with a κ of 95% (95% CI: 89% to 100%). Reflex FISH was performed on 94 breast cancers that had been determined as 2+ immunohistochemically at the time of initial diagnosis. Variable H2T and H2D levels were correlated with corresponding results for the HER2/centromeric probe for chromosome 17 (HER2/CEP17) ratio. Of 94 cases that were 2+ immunohistochemically, 62 (66%), 5 (5%), and 27 (29%) were determined at the same central laboratory as negative (<10.5), equivocal (10.5 ≤H2T≤17.8), and positive (>17.8) by FISH, respectively. (Units of H2T measurement are relative fluorescence [defined as relative peak area x illumination buffer volume] per mm2 of invasive tumor [RF/mm2].) Of 62 FISH-negative cases, 24 (39%), 21 (34%), and 17 (27%) were determined as negative, equivocal, and positive by HERmark®, respectively. Of 5 FISH-equivocal cases, 1 (20%), 2 (40%), and 2 (40%) were determined as negative, equivocal, and positive by HERmark®, respectively. Of 27 FISH-positive cases, 3 (11%), 6 (22%), and 18 (67%) were determined as negative, equivocal, and positive by HERmark®, respectively. Clinical Validity Bates et al. (2011) measured H2T in FFPE primary breast tumors from 98 women treated with trastuzumabbased therapy for metastatic breast cancer. (6) Using subpopulation treatment effect pattern plots, the population was divided into H2T low (H2T <13.8), H2T high (H2T ≥68.5), and H2T intermediate (13.8 ≤H2T<68.5) subgroups. Kaplan-Meier analyses were used to compare groups for time-to-progression (TTP) and overall survival (OS). Cox multivariate analyses were used to identify correlates of clinical outcome. Bootstrapping analyses were used to test robustness of results. TTP improved with increasing H2T until, at the highest levels of H2T, an abrupt decrease in the TTP was observed. Kaplan-Meier analyses demonstrated that patients with H2T low tumors (median TTP, 4.2 months; hazard ratio [HR], 3.7; p<0.001) or H2T high tumors (median TTP, 4.6 months; HR=2.7; p=0.008) had significantly shorter TTP than patients whose tumors were H2T intermediate (median TTP, 12 months). OS analyses yielded similar results. The authors concluded that patients with high levels of H2T may represent a subgroup with de novo resistance to trastuzumab but that these results were preliminary and required confirmation in larger controlled clinical cohorts. Joensuu et al. (2011) reported results of measurement of H2T using HERmark® from formalin-fixed tumor tissue of 899 women (89%) who participated in the FinHer trial (ISRCTN76560285) to determine if very high tumor H2T content influences outcome in early breast cancer treated with adjuvant trastuzumab plus chemotherapy. (7) In a chromogenic in situ hybridization (CISH) test, 197 patients (21.9%) had HER2-positive cancer and were randomly assigned to receive trastuzumab or control. Tumor H2T levels varied greatly, by 1,808-fold. High H2T levels strongly correlated with a positive HER2 status by CISH (P<0.001). Patients with very high H2T (defined by ≥22fold the median of HER2-negative cancers [5.7; range, 0.4-118.4]; 13% of CISH-positive cancers) did not benefit from adjuvant trastuzumab (HR for distant recurrence, 1.23; 95% CI: 0.33 to 4.62; p=0.75), whereas the remaining patients with HER2-positive disease by CISH (87%) did benefit (HR for distant recurrence, 0.52; 95% CI: 0.28 to 1.00; p=0.050). The authors concluded that patients with HER2-positive breast cancer with very high tumor HER2 content may benefit less from adjuvant trastuzumab compared with those whose cancer has more moderate HER2 content. Toi et al. (2010) investigated the relationship between H2T or H2D and OS in 72 patients drawn from 6 oncology clinics in Japan who had metastatic breast cancer and had been treated with at least one chemotherapy regimen before receiving trastuzumab. (8) Patients were originally selected for treatment with trastuzumab by IHC (88%) or FISH (12%). HERmark® assay results were correlated with OS using univariate Kaplan-Meier, hazard function plots, and multivariate Cox regression analyses. Clinical outcome data were drawn from medical chart review. Measurements of H2T and H2D were tested for association with OS, defined as the time from start of trastuzumab treatment to cancer-associated death or end of follow-up (median, 18.2 months). Median duration of trastuzumab treatment was 14.6 months. Overall 2-year survival was 60.8% (95% CI: 48.4% to 73.2%). In univariate analyses, patients were classified into 4 subgroups defined by the 25th, 50th, and 75th percentiles for each of the 3 variables, H2T, H2D, and their ratio, H2D/ H2T. Hazard function plots were estimated in the 4 H2T sub-groups, and sub-groups with the 25% highest and lowest H2T values had substantially lower risk of death than the middle 2 subgroups. Dividing the cohort into high HER2-expressing (≥the median value of H2T) and low HER2-expressing (<the median value of H2T) sub-groups and using Cox regression with the continuous H2T value in each of sub-group, patients with higher HER2 values had longer survival than those with lower H2T values in the high HER2- expressing group (HR=0.06; p=0.010; 95% CI: 0.01-0.51). In contrast, in the low HER2expressing group, the opposite trend (those with lower H2T values were favored) was observed (HR: 16.0; p=0.017; 95% CI: 1.64-155.9). The authors concluded that there are 2 subpopulations of patients in this cohort that behave differently with respect to HER2 expression and OS and that the quantitative amount of HER2 expression measured by HERmark® may be a useful new marker to identify a more relevant target population for trastuzumab treatment in patients with metastatic breast cancer. Lipton et al. (2010) used the HERmark® assay to quantify HER2 expression and examined outcomes in 102 trastuzumab-treated metastatic breast cancer patients previously assessed as IHC 3+ by local but not central IHC, or FISH-positive, and then retested by central FISH. (9) Of 102 metastatic breast cancer patients previously scored as IHC 3+ or 2+/FISH-positive and treated with trastuzumab-containing regimens, 98 had both central FISH and H2T values. Sixty-six (87%) of 76 central FISH-positive patients had high H2T levels (concordant positive), and 19 (86%) of 22 central FISH-negative patients were H2T low (concordant negative). Three (14%) of 22 central FISH-negative patients were H2T high (discordant H2T high), and 10 (13%) of 76 central FISH-positive patients were H2T low (discordant H2T low). The concordant positive group had a significantly longer TTP (median, 11.3 months) compared with the concordant negative group (median, 4.5 months; HR=0.42; p<0.001), and also compared with the discordant H2T low group (median, 3.7 months; HR=0.43; p=0.01). The discordant H2T low group behaved similarly compared with concordant negatives (HR=1; p=0.99). In analyses restricted to central FISH-positive patients only (n=77), Cox proportional hazards multivariate regression identified H2T as an independent predictor of TTP (HR=0.29; p<0.001) and OS (HR =0.19, p< 0.001). The authors concluded that a subset of patients with HER2 gene amplification by FISH express low levels of HER2 protein and have reduced response to trastuzumab-containing therapy, similar to FISH-negative. In a subsequent retrospective analysis of this cohort, Lipton et al. (2013) examined progression-free survival (PFS) and OS in subgroups defined by expression of HER3 (H3T) and p95HER2 (p95), a truncated form of HER2 that does not bind trastuzumab and is a marker of trastuzumab resistance. (10) HER3 and p95 were quantified using VeraTag™ platforms. Results of H3T analysis were available from 89 patients; of these, 61 (69%) were H2T-high (>13.8). Within this group, median PFS was 12.1 months in patients with low H3T (≤3.5) and 5.0 months in patients with high H3T (>3.5; HR=2.7; p=0.002). Median PFS in patients with low H2T (<13.8) was 4.2 months. No significant difference in OS was observed among any groups. In exploratory analysis using regression tree analysis (recursive partitioning), the first split of the tree was based on a H2T cutoff of 16.1, separating patients with low HER2 expression (H2T <16.1) from those with high HER2 expression (H2T ≥16.1). Patients were next segregated by intermediate HER2 expression (16.1 ≤ H2T ≤ 68.3) versus very high HER2 expression (H2T > 68.3). H2T cutoffs of 16.1 and 68.3 to define low, intermediate, and high groups were found to have greater discrimination. Median PFS (15.7 months) and OS (47.6 months) were longest in the subgroup characterized as H2T-intermediate (16.1 ≤H2T≤68.3), H3T-low (≤3.89), and p95 low (≤3.75), compared with other groups (median PFS range, 4.0-7.8 months; median OS range, 23-27 months). In the entire group of HER2-positive, trastuzumabtreated patients, low (normal) H2T (≤16.1) and very high H2T (>68.3) were correlated with shorter PFS and OS. A subsequent study that used VeraTag™ to quantify p95HER2 found significantly shorter PFS and OS among H2Tpositive, hormone receptor-positive, trastuzumab-treated patients with high p95, using a different cutoff of 2.8.11 This association was not found among hormone receptor-negative patients. Han et al. (2012) performed a similar retrospective analysis in 52 women with locally advanced or metastatic HER2-positive (3+ on IHC or gene amplification by FISH) breast cancer that had progressed after treatment with an anthracycline, a taxane, and trastuzumab. (12) Patients were treated with lapatinib and capecitabine until disease progression or intolerance. Among all patients, median TTP was longer in patients with high H2T (>13.8; 5.0 months) than in patients with low H2T (<13.8; 1.8 months; p=0.047). However, a cutoff of 14.95 had greater discrimination (lower chi-square p-value). Results were similar using this cutoff; median TTP in patients with high H2T (>14.95) was 5.2 months and in those with low H2T (<14.95), 1.8 months (p=0.018). No significant association was found between H2T levels and OS using either cut point. Among subgroups defined by H3T levels, median TTP was significantly longer (5.6 months) in patients with both high H2T (>14.95) and high H3T (>0.605) than in other groups (2.2 months; p=0.002). Duchnowska et al. (2012) investigated the correlation between H2T in primary breast cancers and time-to-brain metastasis (TTBM) in HER2+ advanced breast cancer patients treated with trastuzumab. (13) The patient sample included 142 consecutive patients who were administered trastuzumab-based therapy for HER2+ metastatic breast cancer. HER2/neu gene copy number was quantified as the HER2/CEP17 ratio by central laboratory FISH. HER2 protein was quantified as H2T by the HERmark® assay in FFPE tumor samples. HER2 variables were correlated with clinical features, and TTBM was measured from the initiation of trastuzumab-containing therapy. A higher H2T level (continuous variable) was correlated with shorter TTBM, whereas HER2 amplification by FISH and a continuous HER2/CEP17 ratio were not predictive (p =0.013, 0.28, and 0.25, respectively). In the subset of patients that was centrally determined by FISH to be HER2+, an above-the-median H2T level (>58) was significantly associated with a shorter TTBM (HR=2.4. p=0.005), whereas this was not true for the median HER2/CEP17 ratio by FISH (p=0.4). Correlation between a continuous H2T level and TTBM was confirmed on multivariate analysis (HR=3.3, p=0.024). The authors concluded that their data revealed a strong relationship between quantitative HER2 protein expression level and risk for brain relapse in HER2+ advanced breast cancer patients and that quantitative assessment of HER2 protein expression may inform and facilitate refinements in therapeutic treatment strategies for selected subpopulations of patients in this group. Barros et al. (2014) used proximity ligation assays to characterize specific HER2 heterodimers and their association with breast-cancer specific survival (BCSS) and disease-free interval (DFI). (14) Tumor samples were from patients who had primary operable, invasive breast cancer at a single center in England. Among 1858 unselected patients, high levels of all 3 HER2 heterodimers (HER2/HER1 [EGFR], HER2/HER3, HER2/HER4) showed statistically worse BCSS and DFI compared with low levels (range of HRs for BCSS, 0.62-0.66 [95% CIs, 0.45 to 0.92]; p values ≤0.014; range of HRs for DFI, 0.64-0.72 [95% CIs, 0.47 to 0.98]; p values ≤0.037). Cut points were determined using X-tile, a graphical method that has been used in breast cancer research. (15) However, among the subgroup of 224 patients who were HER2-positive by IHC/FISH, associations between HER2 heterodimers and patient outcomes were not statistically significant, regardless of trastuzumab therapy. In a follow-up study, Green et al. (2014) showed that HER2/HER3 heterodimers were significantly associated with shorter BCSS among unselected estrogen receptor-positive patients, but not among estrogen receptor-negative patients.16 Among the subset of HER2-positive patients, there was no association between HER2/HER3 heterodimers and BCSS in estrogen receptor-positive or -negative patients who had or had not received trastuzumab. Section Summary Retrospective studies report an association between H2T levels and survival outcomes. However, for these analyses, different cut points are used and results are variable (see Table 1). Table 1. Summary of studies of HERMark® Clinical Validity Reference Bates (2011) Joensuu 7 (2011) Toi (2010) 8 6 Cutoffs Used Low High <13.8 >68.5 Result a NA ≥125.4 <median b H2T ≥median b H2T Group with intermediate H2T levels experienced longest TTP and OS Patients with HER2-positive breast cancer with very high tumor HER2 content may benefit less from adjuvant trastuzumab than those whose cancer has more moderate HER2 content Patients with higher H2T values (>75%ile) lived longer than those with lower H2T values in the high HER2expressing group Patients with lower H2T values live longer than those with higher H2T values in the low HER2-expressing Favored Group Low Intermediate High Lipton 9 (2010) <13.8 >68.5 Lipton 10 (2013) 12 Han (2012) <16.1 >68.3 <13.8 ≥13.8 Duchnowska 13 (2012) <58 Barros 14 (2014) c ≥58 c Per specific heterodimer studied group Better response to trastuzumab at higher levels of HER2 total expression observed Low H2T and high H2T correlated with shorter PFS and OS TTP was longer in patients with high H2T than in patients with low H2T Correlation between a continuous H2T level and TTBM was confirmed on multivariate analysis Low heterodimer levels favored among unselected patients; no association observed among trastuzumab-treated or -naive HER2-positive patients CISH: chromogenic in situ hybridization; H2T: HER2 protein; NA: not applicable; OS: overall survival; PFS: progression-free survival; TTBM: time to brain metastasis; TTP: time to progression. a Cutoff for very high H2T (≥22-fold the median H2T of cancers HER2-negative by CISH. [5.7]) b Absolute values not reported. c Median H2T level. H2T value of 50 was a better discriminator (smaller p value in Cox models). Clinical Utility Data on the clinical utility of HERmark® are lacking. Clinical trials are needed to understand the relationship between quantitative HER2 expression and homodimer measurements with clinical outcomes in breast cancer patients stratified by the HERmark® assay receiving anti-HER2 therapy in the adjuvant and metastatic settings. Ongoing and Unpublished Clinical Trials A search of ClinicalTrials.gov in October 2015 did not identify any ongoing or unpublished trials that would likely influence this review. Summary of Evidence The evidence for assessment of HER2 status using quantitative total human epidermal growth factor receptor 2 (HER2) protein expression and HER2 homodimer measurement in patients who have breast cancer and are undergoing assessment of HER2 status includes validation studies and retrospective analysis of association between levels and survival outcomes. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Retrospective analysis using HERmark® have shown that the assay may predict a worse response to trastuzumab in certain populations. However, findings have been inconsistent, and no clear association with clinical outcomes has been shown. Additionally, cut points for defining patient groups varied across studies. Clinical utility of the HERmark® assay has not been demonstrated, and clinical trials are needed to determine the impact on clinical outcomes of patients stratified by the HERmark® assay. The evidence is insufficient to determine the effects of the technology on health outcomes. Practice Guidelines and Position Statements NCCN Guidelines on the treatment of breast cancer (version 3.2015) do not address the use of HERmark®. (17) U.S. Preventive Services Task Force Recommendations Not applicable. Medicare National Coverage There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers. Palmetto GBA determines coverage and reimbursement for laboratories that perform molecular diagnostic testing and submit claims to Medicare in Medicare Jurisdiction E (California, Nevada, Hawaii). Palmetto GBA’s decisions apply for all molecular diagnostic tests for Medicare. Palmetto GBA has completed an assessment of HERmark® and determined that the test meets criteria for analytic and clinical validity, and clinical utility as a reasonable and necessary Medicare benefit.18 Effective December 9, 2011, Palmetto GBA will reimburse HERmark® services for patients with breast cancer. References [TOP] 1. DeFazio-Eli L, Strommen K, Dao-Pick T, et al. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13(2):R44. PMID 21496232 2. Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalinfixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18(1):11-21. 3. Monogram biosciences announces HER2:HER3 heterodimer and HER3/PI3K VeraTag™ assays are now available for use in development of cancer therapeutics: November 11, 2008. http://www.businesswire.com/news/home/20081111005841/en/Monogram-Biosciences-AnnouncesHER2HER3-Heterodimer-HER3PI3K-VeraTag. Accessed January 14, 2016. 4. Huang W, Reinholz M, Weidler J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010;134(2):303-311. 5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. 6. Bates M, Sperinde J, Köstler WJ, et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol. 2011;22(9):2014-2020. 7. Joensuu H, Sperinde J, Leinonen M, et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol. 2011;22(9):2007-2013. 8. Toi M, Sperinde J, Huang W, et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer. 2010;10:56. PMID 20178580 9. Lipton A, Köstler WJ, Leitzel K, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 2010;116(22):5168-5178. 10. Lipton A, Goodman L, Leitzel K, et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat. Aug 20 2013. PMID 23959396 11. Duchnowska R, Sperinde J, Chenna A, et al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res. May 15 2014;20(10):2805-2813. PMID 24668646 12. Han SW, Cha Y, Paquet A, et al. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS One. 2012;7(7):e39943. PMID 22848366 13. Duchnowska R, Biernat W, Szostakiewicz B, et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist. 2012;17(1):26-35. PMID 22234627 14. Barros FF, Abdel-Fatah TM, Moseley P, et al. Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Res Treat. Apr 2014;144(2):273-285. PMID 24557338 15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. Nov 1 2004;10(21):7252-7259. PMID 15534099 16. Green AR, Barros FF, Abdel-Fatah TM, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat. May 2014;145(1):33-44. PMID 24706169 17. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer, version 3.2015. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 14, 2016. 18. Palmetto GBA®. MolDX: HERmark assay by Monogram coding and billing guidelines (M00028), last update 06/05/2014. http://www.palmettogba.com/palmetto/MolDX.nsf/DocsCat/MolDx%20Website~MolDx~Browse%20By%2 0Topic~Covered%20Tests~8TVSBJ3016?open&navmenu=Browse%5EBy%5ETopic%7C%7C%7C%7C . Accessed January 14, 2016. 19. Blue Cross Blue Shield Association. Medical Policy Reference Manual. Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers. Policy no. 2.04.76, 2015. Coding [TOP] Codes CPT Number 84999 Description Unlisted chemistry procedure Appendix [TOP] N/A History [TOP] Date 12/13/11 12/19/12 12/09/13 12/17/14 12/08/15 02/09/16 Reason New Policy – Add to Pathology/Laboratory Section. Policy created with literature search through September 2011; considered investigational. Replace policy. Rationale updated based on a literature search through September 2012. Reference 9 added. Other references renumbered. Policy statement unchanged. Updated title in related policy 5.01.514 to include: “Other”. Replace policy. Policy updated with a literature search through July 2013; references 3, 11, and 12 added. No change in policy statement. Reference 14 updated. Annual Review. Policy updated with literature review through September 17, 2014; references 11, 14-16, and 18 added; references 3 and 17 updated. No change to policy statement. Annual Review. Policy reviewed. References unchanged. Policy statement unchanged. Annual Review. Policy updated with literature review through November 12, 2015; no references added; references 3 and 17 updated. No change to policy statement. Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2016 Premera All Rights Reserved. Discrimination is Against the Law Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex. Premera: • Provides free aids and services to people with disabilities to communicate effectively with us, such as: • Qualified sign language interpreters • Written information in other formats (large print, audio, accessible electronic formats, other formats) • Provides free language services to people whose primary language is not English, such as: • Qualified interpreters • Information written in other languages If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator - Complaints and Appeals PO Box 91102, Seattle, WA 98111 Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357 Email [email protected] You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue SW, Room 509F, HHH Building Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Getting Help in Other Languages This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357). አማሪኛ (Amharic): ይህ ማስታወቂያ አስፈላጊ መረጃ ይዟል። ይህ ማስታወቂያ ስለ ማመልከቻዎ ወይም የ Premera Blue Cross ሽፋን አስፈላጊ መረጃ ሊኖረው ይችላል። በዚህ ማስታወቂያ ውስጥ ቁልፍ ቀኖች ሊኖሩ ይችላሉ። የጤናን ሽፋንዎን ለመጠበቅና በአከፋፈል እርዳታ ለማግኘት በተውሰኑ የጊዜ ገደቦች እርምጃ መውሰድ ይገባዎት ይሆናል። ይህን መረጃ እንዲያገኙ እና ያለምንም ክፍያ በቋንቋዎ እርዳታ እንዲያገኙ መብት አለዎት።በስልክ ቁጥር 800-722-1471 (TTY: 800-842-5357) ይደውሉ። ( العربيةArabic): قد يحوي ھذا اإلشعار معلومات مھمة بخصوص طلبك أو.يحوي ھذا اإلشعار معلومات ھامة قد تكون ھناك تواريخ مھمة.Premera Blue Cross التغطية التي تريد الحصول عليھا من خالل وقد تحتاج التخاذ إجراء في تواريخ معينة للحفاظ على تغطيتك الصحية أو للمساعدة.في ھذا اإلشعار اتصل. يحق لك الحصول على ھذه المعلومات والمساعدة بلغتك دون تكبد أية تكلفة.في دفع التكاليف 800-722-1471 (TTY: 800-842-5357)بـ 中文 (Chinese): 本通知有重要的訊息。本通知可能有關於您透過 Premera Blue Cross 提交的 申請或保險的重要訊息。本通知內可能有重要日期。您可能需要在截止日期 之前採取行動,以保留您的健康保險或者費用補貼。您有權利免費以您的母 語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357)。 037338 (07-2016) Oromoo (Cushite): Beeksisni kun odeeffannoo barbaachisaa qaba. Beeksisti kun sagantaa yookan karaa Premera Blue Cross tiin tajaajila keessan ilaalchisee odeeffannoo barbaachisaa qabaachuu danda’a. Guyyaawwan murteessaa ta’an beeksisa kana keessatti ilaalaa. Tarii kaffaltiidhaan deeggaramuuf yookan tajaajila fayyaa keessaniif guyyaa dhumaa irratti wanti raawwattan jiraachuu danda’a. Kaffaltii irraa bilisa haala ta’een afaan keessaniin odeeffannoo argachuu fi deeggarsa argachuuf mirga ni qabaattu. Lakkoofsa bilbilaa 800-722-1471 (TTY: 800-842-5357) tii bilbilaa. Français (French): Cet avis a d'importantes informations. Cet avis peut avoir d'importantes informations sur votre demande ou la couverture par l'intermédiaire de Premera Blue Cross. Le présent avis peut contenir des dates clés. Vous devrez peut-être prendre des mesures par certains délais pour maintenir votre couverture de santé ou d'aide avec les coûts. Vous avez le droit d'obtenir cette information et de l’aide dans votre langue à aucun coût. Appelez le 800-722-1471 (TTY: 800-842-5357). Kreyòl ayisyen (Creole): Avi sila a gen Enfòmasyon Enpòtan ladann. Avi sila a kapab genyen enfòmasyon enpòtan konsènan aplikasyon w lan oswa konsènan kouvèti asirans lan atravè Premera Blue Cross. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kèk aksyon avan sèten dat limit pou ka kenbe kouvèti asirans sante w la oswa pou yo ka ede w avèk depans yo. Se dwa w pou resevwa enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou peye pou sa. Rele nan 800-722-1471 (TTY: 800-842-5357). Deutsche (German): Diese Benachrichtigung enthält wichtige Informationen. Diese Benachrichtigung enthält unter Umständen wichtige Informationen bezüglich Ihres Antrags auf Krankenversicherungsschutz durch Premera Blue Cross. Suchen Sie nach eventuellen wichtigen Terminen in dieser Benachrichtigung. Sie könnten bis zu bestimmten Stichtagen handeln müssen, um Ihren Krankenversicherungsschutz oder Hilfe mit den Kosten zu behalten. Sie haben das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Rufen Sie an unter 800-722-1471 (TTY: 800-842-5357). Hmoob (Hmong): Tsab ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb. Tej zaum tsab ntawv tshaj xo no muaj cov ntsiab lus tseem ceeb txog koj daim ntawv thov kev pab los yog koj qhov kev pab cuam los ntawm Premera Blue Cross. Tej zaum muaj cov hnub tseem ceeb uas sau rau hauv daim ntawv no. Tej zaum koj kuj yuav tau ua qee yam uas peb kom koj ua tsis pub dhau cov caij nyoog uas teev tseg rau hauv daim ntawv no mas koj thiaj yuav tau txais kev pab cuam kho mob los yog kev pab them tej nqi kho mob ntawd. Koj muaj cai kom lawv muab cov ntshiab lus no uas tau muab sau ua koj hom lus pub dawb rau koj. Hu rau 800-722-1471 (TTY: 800-842-5357). Iloko (Ilocano): Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion. Daytoy a pakdaar mabalin nga adda ket naglaon iti napateg nga impormasion maipanggep iti apliksayonyo wenno coverage babaen iti Premera Blue Cross. Daytoy ket mabalin dagiti importante a petsa iti daytoy a pakdaar. Mabalin nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga aldaw tapno mapagtalinaedyo ti coverage ti salun-atyo wenno tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong iti bukodyo a pagsasao nga awan ti bayadanyo. Tumawag iti numero nga 800-722-1471 (TTY: 800-842-5357). Italiano (Italian): Questo avviso contiene informazioni importanti. Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso Premera Blue Cross. Potrebbero esserci date chiave in questo avviso. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente. Chiama 800-722-1471 (TTY: 800-842-5357). 日本語 (Japanese): この通知には重要な情報が含まれています。この通知には、Premera Blue Cross の申請または補償範囲に関する重要な情報が含まれている場合があ ります。この通知に記載されている可能性がある重要な日付をご確認くだ さい。健康保険や有料サポートを維持するには、特定の期日までに行動を 取らなければならない場合があります。ご希望の言語による情報とサポー トが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話 ください。 Română (Romanian): Prezenta notificare conține informații importante. Această notificare poate conține informații importante privind cererea sau acoperirea asigurării dumneavoastre de sănătate prin Premera Blue Cross. Pot exista date cheie în această notificare. Este posibil să fie nevoie să acționați până la anumite termene limită pentru a vă menține acoperirea asigurării de sănătate sau asistența privitoare la costuri. Aveți dreptul de a obține gratuit aceste informații și ajutor în limba dumneavoastră. Sunați la 800-722-1471 (TTY: 800-842-5357). 한국어 (Korean): 본 통지서에는 중요한 정보가 들어 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross 를 통한 커버리지에 관한 정보를 포함하고 있을 수 있습니다. 본 통지서에는 핵심이 되는 날짜들이 있을 수 있습니다. 귀하는 귀하의 건강 커버리지를 계속 유지하거나 비용을 절감하기 위해서 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다. 귀하는 이러한 정보와 도움을 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357) 로 전화하십시오. Pусский (Russian): Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357). ລາວ (Lao): ແຈ້ ງການນ້ີ ມີຂ້ໍ ມູ ນສໍາຄັ ນ. ແຈ້ ງການນ້ີ ອາດຈະມີຂ້ໍ ມູ ນສໍາຄັ ນກ່ ຽວກັ ບຄໍາຮ້ ອງສະ ໝັ ກ ຫື ຼ ຄວາມຄຸ້ ມຄອງປະກັ ນໄພຂອງທ່ ານຜ່ ານ Premera Blue Cross. ອາດຈະມີ ວັ ນທີສໍາຄັ ນໃນແຈ້ ງການນີ້. ທ່ ານອາດຈະຈໍາເປັນຕ້ ອງດໍາເນີນການຕາມກໍານົ ດ ເວລາສະເພາະເພື່ອຮັ ກສາຄວາມຄຸ້ ມຄອງປະກັ ນສຸ ຂະພາບ ຫື ຼ ຄວາມຊ່ ວຍເຫື ຼ ອເລື່ອງ ຄ່ າໃຊ້ ຈ່ າຍຂອງທ່ ານໄວ້ . ທ່ ານມີສິດໄດ້ ຮັ ບຂ້ໍ ມູ ນນ້ີ ແລະ ຄວາມຊ່ ວຍເຫື ຼ ອເປັນພາສາ ຂອງທ່ ານໂດຍບໍ່ເສຍຄ່ າ. ໃຫ້ ໂທຫາ 800-722-1471 (TTY: 800-842-5357). ភាសាែខម រ (Khmer): េសចកត ីជូនដំណឹងេនះមានព័ត៌មានយា៉ងសំខាន់។ េសចកត ីជូនដំណឹងេនះរបែហល ជាមានព័ត៌មានយា៉ងសំខាន់អំពីទរមង់ែបបបទ ឬការរា៉ប់រងរបស់អនកតាមរយៈ Premera Blue Cross ។ របែហលជាមាន កាលបរ ិេចឆ ទសំខាន់េនៅកនុងេសចកត ីជូន ដំណឹងេនះ។ អន ករបែហលជារតូវការបេញច ញសមតថ ភាព ដល់កំណត់ៃថង ជាក់ចបាស់ នានា េដើមបីនឹងរកសាទុកការធានារា៉ប់រងសុខភាពរបស់អនក ឬរបាក់ជំនួយេចញៃថល ។ អន កមានសិទធិទទួ លព័ត៌មានេនះ និងជំនួយេនៅកនុងភាសារបស់អនកេដាយមិនអស លុយេឡើយ។ សូ មទូ រស័ពទ 800-722-1471 (TTY: 800-842-5357)។ ਪੰ ਜਾਬੀ (Punjabi): ਇਸ ਨੋਿਟਸ ਿਵਚ ਖਾਸ ਜਾਣਕਾਰੀ ਹੈ. ਇਸ ਨੋਿਟਸ ਿਵਚ Premera Blue Cross ਵਲ ਤੁਹਾਡੀ ਕਵਰੇਜ ਅਤੇ ਅਰਜੀ ਬਾਰੇ ਮਹੱ ਤਵਪੂਰਨ ਜਾਣਕਾਰੀ ਹੋ ਸਕਦੀ ਹੈ . ਇਸ ਨੋਿਜਸ ਜਵਚ ਖਾਸ ਤਾਰੀਖਾ ਹੋ ਸਕਦੀਆਂ ਹਨ. ਜੇਕਰ ਤੁਸੀ ਜਸਹਤ ਕਵਰੇਜ ਿਰੱ ਖਣੀ ਹੋਵੇ ਜਾ ਓਸ ਦੀ ਲਾਗਤ ਜਿਵੱ ਚ ਮਦਦ ਦੇ ਇਛੁੱ ਕ ਹੋ ਤਾਂ ਤੁਹਾਨੂੰ ਅੰ ਤਮ ਤਾਰੀਖ਼ ਤ ਪਿਹਲਾਂ ਕੁੱ ਝ ਖਾਸ ਕਦਮ ਚੁੱ ਕਣ ਦੀ ਲੋ ੜ ਹੋ ਸਕਦੀ ਹੈ ,ਤੁਹਾਨੂੰ ਮੁਫ਼ਤ ਿਵੱ ਚ ਤੇ ਆਪਣੀ ਭਾਸ਼ਾ ਿਵੱ ਚ ਜਾਣਕਾਰੀ ਅਤੇ ਮਦਦ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਿਧਕਾਰ ਹੈ ,ਕਾਲ 800-722-1471 (TTY: 800-842-5357). ( فارسیFarsi): اين اعالميه ممکن است حاوی اطالعات مھم درباره فرم. اين اعالميه حاوی اطالعات مھم ميباشد به تاريخ ھای مھم در. باشدPremera Blue Cross تقاضا و يا پوشش بيمه ای شما از طريق شما ممکن است برای حقظ پوشش بيمه تان يا کمک در پرداخت ھزينه. اين اعالميه توجه نماييد شما حق. به تاريخ ھای مشخصی برای انجام کارھای خاصی احتياج داشته باشيد،ھای درمانی تان برای کسب.اين را داريد که اين اطالعات و کمک را به زبان خود به طور رايگان دريافت نماييد ( تماس800-842-5357 تماس باشمارهTTY )کاربران800-722-1471 اطالعات با شماره .برقرار نماييد Polskie (Polish): To ogłoszenie może zawierać ważne informacje. To ogłoszenie może zawierać ważne informacje odnośnie Państwa wniosku lub zakresu świadczeń poprzez Premera Blue Cross. Prosimy zwrócic uwagę na kluczowe daty, które mogą być zawarte w tym ogłoszeniu aby nie przekroczyć terminów w przypadku utrzymania polisy ubezpieczeniowej lub pomocy związanej z kosztami. Macie Państwo prawo do bezpłatnej informacji we własnym języku. Zadzwońcie pod 800-722-1471 (TTY: 800-842-5357). Português (Portuguese): Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde ou ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357). Fa’asamoa (Samoan): Atonu ua iai i lenei fa’asilasilaga ni fa’amatalaga e sili ona taua e tatau ona e malamalama i ai. O lenei fa’asilasilaga o se fesoasoani e fa’amatala atili i ai i le tulaga o le polokalame, Premera Blue Cross, ua e tau fia maua atu i ai. Fa’amolemole, ia e iloilo fa’alelei i aso fa’apitoa olo’o iai i lenei fa’asilasilaga taua. Masalo o le’a iai ni feau e tatau ona e faia ao le’i aulia le aso ua ta’ua i lenei fa’asilasilaga ina ia e iai pea ma maua fesoasoani mai ai i le polokalame a le Malo olo’o e iai i ai. Olo’o iai iate oe le aia tatau e maua atu i lenei fa’asilasilaga ma lenei fa’matalaga i legagana e te malamalama i ai aunoa ma se togiga tupe. Vili atu i le telefoni 800-722-1471 (TTY: 800-842-5357). Español (Spanish): Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357). Tagalog (Tagalog): Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon. Ang paunawa na ito ay maaaring naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa pamamagitan ng Premera Blue Cross. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring mangailangan ka na magsagawa ng hakbang sa ilang mga itinakdang panahon upang mapanatili ang iyong pagsakop sa kalusugan o tulong na walang gastos. May karapatan ka na makakuha ng ganitong impormasyon at tulong sa iyong wika ng walang gastos. Tumawag sa 800-722-1471 (TTY: 800-842-5357). ไทย (Thai): ประกาศนี ้มีข้อมูลสําคัญ ประกาศนี ้อาจมีข้อมูลที่สําคัญเกี่ยวกับการการสมัครหรื อขอบเขตประกัน สุขภาพของคุณผ่าน Premera Blue Cross และอาจมีกําหนดการในประกาศนี ้ คุณอาจจะต้ อง ดําเนินการภายในกําหนดระยะเวลาที่แน่นอนเพื่อจะรักษาการประกันสุขภาพของคุณหรื อการช่วยเหลือที่ มีค่าใช้ จ่าย คุณมีสิทธิที่จะได้ รับข้ อมูลและความช่วยเหลือนี ้ในภาษาของคุณโดยไม่มีค่าใช้ จ่าย โทร 800-722-1471 (TTY: 800-842-5357) Український (Ukrainian): Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страхувального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дзвоніть за номером телефону 800-722-1471 (TTY: 800-842-5357). Tiếng Việt (Vietnamese): Thông báo này cung cấp thông tin quan trọng. Thông báo này có thông tin quan trọng về đơn xin tham gia hoặc hợp đồng bảo hiểm của quý vị qua chương trình Premera Blue Cross. Xin xem ngày quan trọng trong thông báo này. Quý vị có thể phải thực hiện theo thông báo đúng trong thời hạn để duy trì bảo hiểm sức khỏe hoặc được trợ giúp thêm về chi phí. Quý vị có quyền được biết thông tin này và được trợ giúp bằng ngôn ngữ của mình miễn phí. Xin gọi số 800-722-1471 (TTY: 800-842-5357).